CLINICAL MARKETS AT STAKE
Australia risks being left behind in the growing clinical trials industry because
it lacks officially recognised qualifications for scientists conducting drug tests
on humans, according to industry leader Andrew Giddy. With just a quarter of 1
per cent of the world market for running early phase trials, there was plenty
of room for growth, said Dr Giddy, chief executive of Nucleus Networks.